$EDIT SEC Filings

Filed On	Filing
08 Oct 2026	8-K: Regulation FD Disclosure; Other Events Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering
09 Sep 2026	Form 4: Ory Daniel Scott, EVP, Chief Medical Officer Granted 950,000 Stock Option (right to buy)
09 Sep 2026	Form 3: Ory Daniel Scott, EVP, Chief Medical Officer No securities owned
09 Sep 2026	S-8
08 Sep 2026	EFFECT
04 Sep 2026	Form 4: Parison Amy, SVP, Chief Financial Officer Sold 453 shares ($1.38K)
04 Sep 2026	Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER Sold 709 shares ($2.15K)
04 Sep 2026	Form 4: O'Neill Gilmore Neil, Director Sold 5,124 shares ($15.6K)
31 Aug 2026	144
31 Aug 2026	144
31 Aug 2026	S-3
14 Aug 2026	SCHEDULE 13G
07 Aug 2026	Form 4: Ellinor Patrick Thomas Ii, Director Granted 103,400 Stock Option (right to buy)
07 Aug 2026	Form 3: Ellinor Patrick Thomas Ii, Director No securities owned
05 Aug 2026	Form 4: Parison Amy, SVP, Chief Financial Officer Sold 678 shares ($1.75K)
05 Aug 2026	10-Q
05 Aug 2026	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
29 Jul 2026	Form 4: Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER Sold 4,928 shares ($13.2K)
29 Jul 2026	SCHEDULE 13G/A
21 Jul 2026	144

Comments